CCRM Nordic Welcomes Frank Waldron-Lynch to the Board of Directors

CCRM Nordic is proud to announce the appointment of Frank Waldron-Lynch to its Board of Directors. As a seasoned leader in the biotechnology sector and a key figure at AstraZeneca, Dr. Waldron-Lynch brings a wealth of experience and insight to the board.

With the addition of Dr. Waldron-Lynch, the board gains a valuable perspective that will further enhance CCRM Nordic’s mission to support Sweden’s growing advanced therapy medicinal products (ATMPs) startup companies, research, and investors.

“We are thrilled to welcome Frank to the board,” said Jan Nilsson, CCRM Nordic Chair. “His expertise in the biotechnology and ATMP sectors will be instrumental as we continue to drive innovation and growth within the industry.”

Frank Waldron-Lynch’s appointment comes at a pivotal time as CCRM Nordic prepares to expand its business and technology platforms, aiming to become a powerhouse in the field of regenerative medicine.

For more information, please contact: Fredrik Wessberg, fredrik.wessberg@ccrmnordic.se

About CCRM Nordic:

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs.

About CCRM:

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca